Effect of Tanreqing injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei

Chinese Journal of Integrative Medicine

Volumn 16, Issue 2, 2010, Pages 131-137

  Li, Wen ^a,b   Mao, Bing ^a   Wang, Gang ^a   Wang, Lei ^a   Chang, Jing ^a   Zhang, Ying ^a   Wan, Mei Hua ^a   Guo, Jia ^a   Zheng, Yu Qiong ^b  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Acute exacerbation of chronic obstructive pulmonary disease; Interleukin 8; Neutrophil elastase; Randomized controlled trial; Retention of phlegm and heat in Fei; Tanreqing injection

Indexed keywords

AMBROXOL; AMINOPHYLLINE; BUDESONIDE; CHINESE DRUG; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TANREQING; TERBUTALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE MEDICINE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; AGED; BODY TEMPERATURE; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HOT TEMPERATURE; HUMANS; INJECTIONS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME; TREATMENT OUTCOME;

EID: 77954506965     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-010-0131-y     Document Type: Article

References (23)

1. Global strategy for the diagonsis, management, and prevention of chronic obstrutive lung disease. Updated 2008. http//www.goldcopd.org
2. Bao TY. A review on treating COPD in Chinese medicine. Chin J Pract Mod Med (Chin) 2008;21:397-399.
3. Peng B, Zhang NH, Ji HY, Li GL, Ren W, Chen W. Effect of Tanreqing on chronic obstructive pulmonary disease (pulmonary retention of phlegm pyrexia). J Emerg Tradit Chin Med (Chin) 2007;16:1456-1457.
4. Zhang HJ, Wei ZL. Effect of Tanreqing on chronic obstructive pulmonary disease combined with infection. Med Forum Basic (Chin) 2006;10:1150-1150.
5. Chinese Sociey of Respiratory Diseases. Diagnosis and treatment guidance of chronic obstructive pulmonary disease. Chin Tuberc Respir Dis (Chin) 2002;25: 453-460.
6. Zheng XY. Guiding principle of clinical research on new drugs of Chinese medicine. Bejing: China Medico-Pharmaceutical Sciences and Technology Publishing House; 2002:54-58.
7. Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, Xu D, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease. Acta Pharmacol Sin 2007;828:1166-1174. (Pubitemid 47197779)
8. Sitompul PA, Sutoyo DK, Antariksa B, Kadarsih R. Contribution lower airway bacterial colonization to persistent airway lumen inflammation and progression of airway disease in chronic obstructive pulmonary disease. Respirology (Suppl) 2008;13:102-110.
9. Devalia JL, Mills PR, Sapsford RJ, Seemungal T, Davies RJ. The effect of exposure to diesel exhaust particles (DEP) on IL-8 release from bronchial epithelial cells cultured from biopsies of non-smokers, smokers with normal pulmonary function and patients with chronic obstructive pulmonary disease (COPD). Allergy 1998;53:64.
10. Sullivan A, Gompertz S, Bayley D, Stockley R. Sputum eosinophilia in chronic obstructive pulmonary disease (COPD): relationship with interleukin-8 (IL-8) in spontaneous and induced sputum sol. Thorax (Suppl) 2001;56:iii80-iii81.
11. Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. PuIm Pharmacol Ther 2003;16:247-277. (Pubitemid 36870860)
12. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147-159.
13. Currie GP, Butler CA, Anderson WJ, Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease:a new approach to oral treatment. Br J Clin Pharmacol 2008;65:803-810.
14. Cianchetti S, Bacci E, Bartoli ML, Ruocco L, Pavia T, Dente FL, et al. Can hypertonic saline inhalation influence preformed chemokine and mediator release in induced sputum of chronic obstructive pulmonary disease patients?Comparison with isotonic saline. Clin Exp Allergy 2007;37:1819-1826.
15. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004;13:1649-1656.
16. Cai BQ, Zhu YJ, Xu L, Zhang H, Guo ZJ, Ma Y, et al. Clinical analysis of Huayu Kechuan tabletse (814) in patients with chronic obstructive pulmonary disease(312 cases). Bull Med Res (Chin) 2002;4(31):14-18.
17. Wang S, Zhang NZ, Ji HY, Li ZG. Yifei Jianpi Chinese medicine on airway inflammation of chronic obstructive pulmonary disease. Chin J Integr Tradit Med (Chin) 2002;22:462.
18. Zhang LL, Li Z, Xu XY, Li YM. Pharmacodynamic study of Tanreqing capsule. Chin J Exp Tradit Med Form (Chin) 2004; 10(3):37-40.
19. Gao YM, Wang ZS. Preliminary evaluation of clinical pharmacy of Tanreqing injection. Capital Med (Chin) 2004;11(12):44-46.
20. Huang B, Huang QX, Lu DS, Xie CM. Clinical research of Tanreqing Injection on acute exacerbation of chronic obstructive pulmonary disease. J Emerg Tradit Chin Med (Chin) 2006:5:464-466.
21. Xu CQ. Effect of Tanreqing Injection on cytokines and pulmonary function in patients with COPD. Pract Gen Med (Chin) 2006;4:401-402.
22. Zhang Y, Li TQ, Wang G, Chang J, Mao B, Wang L, et al. Randomized controlled trial of Tanreqing Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (syndrome of retention of phlegm-heat in the lung). Chin J Evid-Based Med (Chin) 2004;4:300-306.
23. Zhu YQ. The effect of ambroxola against airway inflammation of patients with chronic obstructive pulmonary disease. Hainan Med (Chin) 2006;12(17):6-7.